Table IV.
Pharmacokinetic Parameters of Fenoterol after Oral Administration of Different Formulas
| Pharmacokinetic parameter | F16 | F23 | F30 | Berotec® |
|---|---|---|---|---|
| Cmax (ng/mL) | 80.9 ± 1.8 | 69.95 ± 3.31 | 61.23 ± 8.06 | 146.52 ± 21.52 |
| Tmax (h) | 5.83 ± 1.83 | 6.16 ± 1.6 | 4.33 ± 1.36 | 1.33 ± 0.51 |
| AUC 0–24 | ||||
| (ng/ml * h) | 750.669 ± 54.8 | 627.59 ± 92.9 | 468.28 ± 105.01 | 681.66 ± 68.02 |
 (ng/ml * h) |
819.47 ± 40.6 | 718.19 ± 80.03 | 499.28 ± 115.4 | 708.25 ± 59.09 |
| HVDt50%Cmax | ||||
| (h) | 6.81 ± 0.67 | 6.52 ± 2.11 | 4.92 ± 1.33 | 2.71 ± 0.68 |
| RD | 2.51 | 2.41 | 1.82 | 1 |
| K (h−1) | 0.11 ± 0.03 | 0.09 ± 0.03 | 0.13 ± 0.02 | 0.13 ± 0.02 |
| t 1/2 (h) | 6.25 ± 1.73 | 8.68 ± 3.21 | 5.6 ± 0.96 | 5.31 ± 1.05 |
| MRT (h) | 10.93 ± 1.25 | 12.61 ± 2.16 | 9.49 ± 1.20 | 7.03 ± 0.76 |
All formulae between the same brackets are not significantly different from each other but differ significantly from those included in other brackets (P < 0.001)
Cmax (ng/ml): (Commercial) (F16, F23, F30), AUC(0–24) (ng/ml.hr): (Commercial, F16, F23), (F30), 
(ng/ml.hr): (Commercial, F16, F23), (F30), t1/2(hr): (Commercial, F16, F23, F30), Tmax (hr): (Commercial), (F16, F23, F30), HVDt50%Cmax (h): (Commercial) (F16, F23, F30), MRT (hr): (Commercial), (F16, F23), (F30)